MGC Pharmaceuticals Limited SPP -- Extension of Closing Date (3536J)
August 15 2023 - 1:29AM
UK Regulatory
TIDMMXC
RNS Number : 3536J
MGC Pharmaceuticals Limited
15 August 2023
SPP - Extension of Closing Date
15 August 2023
ASX Code: MXC
LSE Code: MXC
MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company) refers
to its prospectus lodged with ASIC and released on the ASX on 3
August 2023 in relation to its security purchase plan (SPP), as
first announced to the ASX on 1 August 2023 (Prospectus).
Defined terms used in this announcement have the meaning given
to them in the Prospectus, unless specified otherwise.
The Company wishes to advise that the Closing Date for the SPP
has been extended from 5:00pm (AWST) on Friday, 18 August 2023
until 5:00pm (AWST) on Friday, 25 August 2023. The Company has also
released an updated Appendix 3B reflecting the extended Closing
Date.
The SPP timetable has been revised as follows:
Action Date
Record Date for SPP 5:00pm (AWST) on 31 July 2023
------------------------------
Announcement of SPP and lodgment of Appendix 3B with ASX 1 August 2023
------------------------------
Lodgment of Prospectus for issue of SPP Securities with ASIC and ASX 3 August 2023
------------------------------
Opening date of the SPP Offer under the Prospectus 4 August 2023
------------------------------
Closing Date of the SPP Offer under the Prospectus** 25 August 2023
------------------------------
Announcement of the results of the SPP 29 August 2023
------------------------------
Issue of SPP Shares and lodgement of Appendix 2A for the SPP Shares with ASX 1 September 2023
------------------------------
General Meeting to approve the issuance of the SPP Options 5 September 2023
------------------------------
Issue of SPP Options and lodgement of forms for the SPP Options with ASX 6 September 2023
------------------------------
*The above dates are indicative only and may change without
prior notice.
**Subscribers under the SPP Offer should ensure that they have
lodged their SPP Application Form by this date.
Further details of the SPP Offer, including details on how to
apply under the SPP Offer and key risks associated with an
investment in the Company are set out in the Prospectus.
Applications for new Shares and free attaching Options (subject to
Shareholder approval at the upcoming general meeting) under the SPP
Offer may only be made by completing the Application Form
accompanying the Prospectus in accordance with the instructions
outlined on the Application Form. Shareholders eligible to
participate in the SPP Offer should read the Prospectus carefully
and consult their professional advisers as necessary.
-Ends-
Authorised for release by the board of directors, for further
information please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6555 2950 +61 8 6555 2950
info@mgcpharma.co.uk info@mgcpharma.co.uk
UK IR/PR Advisers UK Brokers
IFC Advisory Oberon Capital
Graham Herring / Tim Metcalfe Aimee McCusker / Adam Pollock
/ Zach Cohen +44 203 179 5300
+44 203 934 6630 aimeemccusker@oberoninvestments.com
mgcpharma@investor-focus.co.uk adampollock@oberoninvestments.com
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
pharmaceutical company, focused on developing and supplying
accessible and ethically produced plant derived medicines,
combining in-house research with innovative technologies, with the
goal of finding or producing treatments to for unmet medical
conditions.
The Company's founders and executives are key figures in the
global pharmaceuticals industry and the core business strategy is
to develop and supply high quality plant derived medicines for the
growing demand in the medical markets in Europe, North America and
Australasia.
MGC Pharma has a robust development pipeline targeting two
widespread medical conditions and has further products under
development.
MGC Pharma has partnered with renowned institutions and academia
to optimise the development of targeted plant derived medicines, to
be produced in the Company's EU-GMP Certified manufacturing
facilities.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels:
LinkedIn: MGC Pharmaceuticals Ltd.
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUVUNROOUWARR
(END) Dow Jones Newswires
August 15, 2023 02:29 ET (06:29 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Apr 2024 to May 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From May 2023 to May 2024
